EC approves Sobi-ADC's Zynlonta for diffuse large B-cell lymphoma
The EC has granted conditional marketing authorisation for Sobi and ADC Therapeutics’ Zynlonta to treat diffuse large B-cell lymphoma.
Source: pharmaceutical-technology.com
Sobi Research Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sobi Research Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sobi Research Development Today - Breaking & Trending Today